Bivalent Covid-19 Booster

The NextCOVE Study will evaluate an investigational bivalent vaccine known as mRNA-1283.222 that may protect people from getting sick if they come into contact with the virus that causes COVID-19 and multiple variants, including the Omicron variant.

Participation in the NextCOVE Study lasts approximately 13 months and includes up to 6 trial site visits and 3 safety phone calls.

In order to participate, you or your child must:

  • Be at least 12 years old
  • Have received a COVID-19 vaccine and at least 1 booster dose of a COVID-19 vaccine if age 18 or older
  • Not have a positive COVID-19 test within 3 months prior to the screening visit
  • Be free from exposure to someone with SARS-CoV-2 infection or COVID-19 within 2 weeks prior to receiving the first vaccination
  • Not have received a COVID-19 vaccine within 3 months prior to the screening visit

There are additional eligibility requirements, which the trial doctor can explain to you.